Data gathered: September 28
Alternative Data for Cytokinetics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 34 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 58 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 15 | Sign up | Sign up | Sign up |
| Facebook Followers | 639 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,049 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,790 | Sign up | Sign up | Sign up |
| Twitter Mentions | 39 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 451 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 58 | Sign up | Sign up | Sign up |
| Linkedin Employees | 507 | Sign up | Sign up | Sign up |
About Cytokinetics
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
| Price | $52.34 |
| Target Price | Sign up |
| Volume | 860,960 |
| Market Cap | $6.19B |
| Year Range | $47.86 - $84.8 |
| Dividend Yield | 0% |
| Analyst Rating | 79% buy |
| Industry | Biotechnology |
In the news
 |
ProShare Advisors LLC Sells 2,600 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)September 28 - ETF Daily News |
|
Pacer Advisors Inc. Has $1.01 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)September 28 - ETF Daily News |
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific SessionsSeptember 27 - GlobeNewswire |
|
Cytokinetics Incorporated : Beta blocker Use and Incidence of New Atrial Fibrillation or Flutter Requiring Therapy in Post septal Myectomy Hypertrophic Cardiomyopathy PatientsSeptember 27 - Finnhub |
|
|
Marshall Wace LLP Cuts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)September 25 - ETF Daily News |
|
Contrasting Earth Science Tech (OTCMKTS:ETST) and Cytokinetics (NASDAQ:CYTK)September 24 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 250,000 | 51M | -51M | -143M | -128M | -1.310 |
| Q1 '24 | 840,000 | 46M | -52M | -136M | -124M | -1.330 |
| Q4 '23 | 1.7M | 44M | -50M | -137M | -121M | -1.380 |
| Q3 '23 | 380,000 | 40M | -47M | -129M | -115M | -1.350 |
| Q2 '23 | 870,000 | 40M | -46M | -129M | -115M | -1.340 |
Insider Transactions View All
| Malik Fady Ibraham filed to sell 120,920 shares at $56.8. September 17 '24 |
| Malik Fady Ibraham filed to sell 122,920 shares at $56.8. September 17 '24 |
| Blum Robert I filed to sell 397,456 shares at $56. September 17 '24 |
| PARSHALL B LYNNE filed to sell 20,600 shares at $54.9. September 9 '24 |
| Blum Robert I filed to sell 397,456 shares at $57. September 3 '24 |
Similar companies
Read more about Cytokinetics (CYTK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Cytokinetics?
The Market Cap of Cytokinetics is $6.19B.
What is the current stock price of Cytokinetics?
Currently, the price of one share of Cytokinetics stock is $52.34.
How can I analyze the CYTK stock price chart for investment decisions?
The CYTK stock price chart above provides a comprehensive visual representation of Cytokinetics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cytokinetics shares. Our platform offers an up-to-date CYTK stock price chart, along with technical data analysis and alternative data insights.
Does CYTK offer dividends to its shareholders?
As of our latest update, Cytokinetics (CYTK) does not offer dividends to its shareholders. Investors interested in Cytokinetics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cytokinetics?
Some of the similar stocks of Cytokinetics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.